InMed Pharmaceuticals Inc. Files Current Report
Ticker: INM · Form: 8-K · Filed: Jan 22, 2025 · CIK: 1728328
Sentiment: neutral
Topics: corporate-filing, contact-information
TL;DR
InMed Pharma updated its address and contact info in an 8-K filing on Jan 22, 2025.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on January 22, 2025, reporting a current event. The filing indicates the company's principal executive offices are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C., Canada, V6C 3E8. The company's telephone number is (604) 669-7207.
Why It Matters
This 8-K filing provides updated contact and location information for InMed Pharmaceuticals Inc., which is important for investors and stakeholders to maintain accurate records.
Risk Assessment
Risk Level: low — This filing is administrative and does not contain material financial or operational information that would typically indicate a change in risk.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer of the 8-K report
- January 22, 2025 (date) — Date of the earliest event reported
- Vancouver, B.C., Canada (location) — Location of principal executive offices
- (604) 669-7207 (phone_number) — Company's telephone number
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating a current event for InMed Pharmaceuticals Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on January 22, 2025.
Where are InMed Pharmaceuticals Inc.'s principal executive offices located?
InMed Pharmaceuticals Inc.'s principal executive offices are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C., Canada, V6C 3E8.
What is the company's telephone number?
The company's telephone number, including area code, is (604) 669-7207.
What is the company's state of incorporation?
The company's state of incorporation is British Columbia.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-22 10:18:33
Filing Documents
- ea0228337-8k_inmed.htm (8-K) — 27KB
- ea022833701ex99-1_inmed.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-005263.txt ( ) — 227KB
- inm-20250122.xsd (EX-101.SCH) — 3KB
- inm-20250122_lab.xml (EX-101.LAB) — 33KB
- inm-20250122_pre.xml (EX-101.PRE) — 22KB
- ea0228337-8k_inmed_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 22, 2025, the Company announced it has been granted an international Patent Cooperation Treaty (PCT') patent in the first of several jurisdictions where the patent has been filed. The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated January 22, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: January 22, 2025 By: /s/ Eric A Adams Eric A Adams President & CEO 2